Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of fitusiran prophylaxis in boys aged 1 to under 12 years with hemophilia A or B, with or without inhibitors
CTR20261519Phase 3Active
- Sponsor
- Sanofi
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Feb 2026; status: active.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on CTR20261519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261519.